Changes in oxidative stress intensity in blood of tumor-bearing rats following different modes of administration of rhenium-platinum system

Shamelashvili, K. L.; Штеменко, Н. I.; Leus, Inga V.; Babiy, Svetlana; Shtemenko, O. V.

doi:10.15407/ubj88.04.029

Cited by 12 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different changes in the secondary structure of the homological proteins were shown in the complexes with configuration isomers. Similar investigations were accomplished with native bovine erythrocyte SOD with the changing of the method of Trp-fluorescence on Tyr-fluorescence [95]. Binding of both complexes to His moieties and changing of the secondary structures of the enzyme did not influence its active center .…”

Section: Fig 7 Level Of Mda In Plasma Of Control (C) Rats and Tumormentioning

confidence: 63%

Rhenium–platinum antitumor systems

Shtemenko¹,

Штеменко²

2017

Ukr.Biochem.J.

Self Cite

View full text Add to dashboard Cite

this review provides an overlook of design (in short), antitumor and other biological activity of quadruple-bonded cluster dirhenium (III) design of quadruple bonded dirhenium(III) clusters, their spectral and antiradical properties (in short); interaction of the dirhenium(III) compounds with lipids and formation of liposomes; interaction of the dirhenium(III) compounds with erythrocytes and their antihemolytic activity in the models of hemolytic anemia; anticancer activity of dirhenium clusters and work of the rhenium-platinum antitumor system; antianemic and antioxidant properties of the dirhenium(III) compounds in the model of tumor growth; interaction

show abstract

Section: Fig 7 Level Of Mda In Plasma Of Control (C) Rats and Tumormentioning

confidence: 63%

Rhenium–platinum antitumor systems

Shtemenko¹,

Штеменко²

2017

Ukr.Biochem.J.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Animal model. The animal model was described previously [3]. Tumor transplantation was performed by subcutaneous injection of 20 % Guerin's carcinoma (T8) cell suspension in the thigh area.…”

Section: Methodsmentioning

confidence: 99%

“…It is known, that transplatin in contrast to cisplatin has no cytotoxic activity due to the inability of the transisomer to form 1,2-GpG intrastrand crosslinks, because of the 180° angle between its two semi-labile chloride ligands, but the substitution of the ammine ligand(s) in transdiamminedichloroplatinum(II) with bulky, planar Ndonor ligands affords trans-platinum(II) complexes with high in vitro cytotoxicity, equivalent to their corresponding cis-isomers and cisplatin [2]. Structure -reactivity relationship investigations of the dirhenium(III) complexes with different ligands and their orientation around the cluster Re 2 6+ fragment showed that trans-diisobutirates and trans-dipivalates had the same anticancer ac-tivity in vivo as their cis-analogs [3], but differed in biochemical behavior, i.e. in antioxidant properties.…”

Section: Literature Reviewmentioning

confidence: 99%

Determination of the anticancer properties of cis- and trans-diadamanthylcarboxylates of dirhenium(III)

Штеменко

Polokhina

Golichenko

et al. 2020

SR: BS

View full text Add to dashboard Cite

The aim of the study. The aim of the work was to investigate in vivo anticancer activity of cis- and trans-diadamanthylcarboxylates of dirhenium(III) alone and together with cisplatin in form of nanobins.Materials and methods. Model of tumor growth, Guerin’s carcinoma; intraperitoneal administration of cisplatin, dirhenium(III) compounds in liposomes and of binary liposomes, containing both cytostatics; volumes and final weights of tumors were measured.Results. In vivo antitumor properties of two dirhenium(III) dicarboxylates with 1-adamantanecarboxylic acid moieties as ligands with cis- (I) and trans- (II) orientation of the carboxylic groups around a cluster fragment alone and together with cisplatin were presented; an attempt to understand differences in a possible mechanism of anticancer activity of the substances were undertaken. Antiradical and DNA-binding properties of I and II were the matter of consideration.Conclusions. Cis- and trans- compounds of dirhenium I and II had close antitumor activity in vivo with a little bit superiority of the cis- analog. Mechanisms of anticancer activity of I and II are different and may also include monofunctional adduct formation and subsequent interstrand cross-linking for the II substance, formation of protein-DNA cross-links, etc.

show abstract

“…A highly significant synergism has been observed between dichlorotetra-μ-isobutyratodirhenium (ІІІ) complexes and cisplatin in tumor-bearing Wistar rats, transplanted with T8 Guerin's carcinoma cells, with a nearly complete regression of the tumors. These remarkable anticancer properties were associated with a strong anti-oxidant effect, with a decrease in lipid peroxidation (LP), as shown by a decrease in plasma concentrations of thiobarbituric active substances (TBA) and an increase of the activity of superoxide dismutase (SOD) in erythrocyte hemolysates [105].…”

Section: Rhenium Complexes and Oxidative Stressmentioning

confidence: 99%

Design of Rhenium Compounds in Targeted Anticancer Therapeutics

Collery¹,

Desmaële

Veena

2019

CPD

View full text Add to dashboard Cite

Background: Many rhenium (Re) complexes with potential anticancer properties have been synthesized in the recent years with the aim to overcome the clinical limitations of platinum agents. Re(I) tricarbonyl complexes are the most common but Re compounds with higher oxidation states have also been investigated, as well as hetero-metallic complexes and Re-loaded self-assembling devices. Many of these compounds display promising cytotoxic and phototoxic properties against malignant cells but all Re compounds are still at the stage of preclinical studies. Methods: The present review focused on the rhenium based cancer drugs that were in preclinical and clinical trials were examined critically. The detailed targeted interactions and experimental evidences of Re compounds reported by the patentable and non-patentable research findings used to write this review. Results: In the present review, we described the most recent and promising rhenium compounds focusing on their potential mechanism of action including, phototoxicity, DNA binding, mitochondrial effects, oxidative stress regulation or enzyme inhibition. Many ligands have been described that modulating the lipophilicity, the luminescent properties, the cellular uptake, the biodistribution, and the cytotoxicity, the pharmacological and toxicological profile. Conclusion: Re-based anticancer drugs can also be used in targeted therapies by coupling to a variety of biologically relevant targeting molecules. On the other hand, combination with conventional cytotoxic molecules, such as doxorubicin, allowed to take into profit the targeting properties of Re for example toward mitochondria. Through the example of the diseleno-Re complex, we showed that the main target could be the oxidative status, with a down-stream regulation of signaling pathways, and further on selective cell death of cancer cells versus normal cells.

show abstract

Changes in oxidative stress intensity in blood of tumor-bearing rats following different modes of administration of rhenium-platinum system

Abstract: effects of the different modes of administration of dichlorotetra-μ-isobutyratodirhenium(ІІІ) -І -(in

Cited by 12 publications

References 18 publications

Rhenium–platinum antitumor systems

Rhenium–platinum antitumor systems

Determination of the anticancer properties of cis- and trans-diadamanthylcarboxylates of dirhenium(III)

Design of Rhenium Compounds in Targeted Anticancer Therapeutics

Contact Info

Product

Resources

About